FIELD-LAB is a drug discovery facility that will help you to speed up the development and market launch of new nuclear drugs for cancer treatment. Through supply of small batches of radio chemicals and radio pharmaceuticals, we meet the need of Bio Pharma scientists and start-up ventures for research materials. This will drive both their ambitions to develop a new drug.
FIELD-LAB is part of a unique and complete nuclear infrastructure.
Read more about Nuclear Infrastructure
Currently, research is done on the production and development of various isotopes:
Read more
Learn more about FIELD-LAB and its importance. Discover our global network for pre-clinical and clinical research: research that is part of the development of every new medical product.
FIELD-LAB is created for and together with partners from different backgrounds. Some of the finest Dutch and British UMC’s have committed themselves to be part of this initiative. They believe in the beneficial results that will be brought to the Nuclear Medicine society. In addition, the partnerships that arise from FIELD-LAB form a portal to a fast growing network, which results in an open innovation environment.
The major bottleneck for research and development of radiopharmaceuticals for targeted alpha therapy is its limited availability. The irradiation of radium-226 could be a game changer as the amounts produced using this method could fulfill the market needs for alpha-emitters. However, there are several challenges in 226Ra target preparation and further processing of irradiated targets.
During the NVNG Spring Conference of last Friday our R&D manager Karlijn van der Schilden provided insight into the current developments of NRGǀPALLAS in the field of developing new production routes for existing and new isotopes. With inextricably linked the subject of securing availability and supply.
Karlijn van der Schilden
R&D Manager Medical Isotopes
T. +31 224 56 8018
M. codee@nrg.eu
Richard van Rijnsoever
Commercial Manager
T. +31 (0)6 2909 6427
M. richard.vanrijnsoever@pallasreactor.com